June 03, 2014

Transfer of Assets

On 3 June 2014, the Board of Directors of Samsung Electronics approved the transfer of assets (biopharmaceutical technology) to Samsung Biologics Co., Ltd., an affiliated company of Samsung Electronics. Samsung Biologics is a global company manufacturing and research and development of biopharmaceutical products. The company is committed to quality-driven manufacturing of biopharmaceutical products and supports both collaborative novel drug development and high-quality, fast-turnaround contract manufacturing partnerships.


▫ Details

1. Date of Transfer (scheduled): 5 June 2014

2. Items of Transfer: Biopharmaceutical technology

3. Value of Transfer: KRW 10,433,000,000
* The value of transferrable asset was determined by an external auditor.
The currency rate of 1,024.3 KRW/Dollar (FX rate on 4 June 2014) was used
to determine the value.

4. Attendance of Independent Director at the BoD meeting: 5 (100%)

5. Attendance of Audit Committee members at the BoD meeting: Yes (100%)